Hints of hope for nebulizer treatment
An inhaled treatment for COVID-19 cut the risk of severe disease — such as that resulting in the need of a ventilator — by 79% in a small preliminary trial of people hospitalized in the United Kingdom. The treatment involves inhaling a protein called interferon beta, which is naturally produced to fight off infection, directly into the lungs. UK biotech company Synairgen has not yet released the results in full for peer review.BBC | 6 min read
Reference: Synairgen webinar
No hay comentarios:
Publicar un comentario